MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Endovascular Treatment of Cerebral Aneurysms
Current devices, emerging therapies, and future technology for the management of cerebral aneurysms.
By David Fiorella, MD, PhD; Michael E. Kelly, MD; Raymond D. Turner IV, MD; and Pedro Lylyk, MD
Flow Diversion for Intracranial Aneurysm Treatment
How this new technology may expand the types of intracranial aneurysms that can be treated.
By David Fiorella, MD, PhD; Michael Kelly, MD; and Henry Woo, MD
Analysis of Possible Factors Related to Periprocedural Events in SAMMPRIS Published
October 1, 2012—In Stroke, David Fiorella, MD, et al, published a detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in the SAMMPRIS trial (2012;43:2682–2688).
SNIS Publishes Commentary Affirming Benefits of Direct Transport to CSCs for ELVO Patients
December 19, 2023—The Society of NeuroInterventional Surgery (SNIS) announced the publication of an Editor’s Column by David Fiorella, MD, et al in the Journal of NeuroInterventional Surgery (JNIS), in which leaders of the society conclude that the entire body of research, including evidence from two new prospective trials, clearly confirm that most patients with emergent large vessel occlusions (ELVOs) benefit from triage directly to comprehensive stroke centers (CSCs).
Enrollment Begins in MARRS Pivotal Trial of Perfuze Millipede System
November 7, 2023—Perfuze, an Ireland-based medical device company developing technology to treat acute ischemic stroke, recently announced commencement of enrollment in its pivotal MARRS clinical study.
Medtronic to Acquire Scientia Vascular
March 10, 2026—Medtronic announced it has entered into a definitive agreement to acquire Scientia Vascular, a developer of access products for the treatment of complex neurovascular conditions.
Embolization Therapies
By Barry T. Katzen, MD, Chief Medical Editor
STEM Trial Approved for Balt’s Squid Liquid Embolic Device
May 14, 2020—Balt announced investigational device exemption (IDE) approval from the FDA to begin STEM, the Squid trial for the embolization of the middle meningeal artery (MMA) to treat chronic subdural hematoma (cSDH).
Rapid Medical’s Tigertriever 13 Thrombectomy Device Gains FDA Clearance
July 25, 2022—Rapid Medical, a developer of neurovascular devices, announced FDA 510(k) clearance for Tigertriever 13 for large vessel occlusions at the 19th annual meeting of the Society of NeuroInterventional Surgery, held July 25-29 in Toronto, Canada.
MicroVention's LVIS Devices Approved for Stent-Assisted Coil Embolization of Intracranial Aneurysms
May 31, 2018—MicroVention, Inc., a United States–based subsidiary of Terumo, announced US Food and Drug Administration (FDA) premarket approval for the LVIS (low-profile visualized intraluminal support) and LVIS Jr.
Cerenovus’ Emboguard Balloon Guide Catheter Launched for Acute Ischemic Stroke Treatment
February 7, 2022—Cerenovus, part of Johnson & Johnson Medical Devices Companies, announced the launch of Emboguard, a next-generation balloon guide catheter to be used in endovascular procedures, including those for patients with acute ischemic stroke.
First Patients Enrolled in STEM Trial of Balt’s Squid Liquid Embolic Agent
December 1, 2020—Balt announced that the first patients have been enrolled in STEM, the Squid trial for the embolization of the middle meningeal artery (MMA), which is evaluating the company’s Squid liquid embolic agent to treat chronic subdural hematoma (cSDH).
Perfuze’s Millipede 088 Access Catheter for Acute Ischemic Stroke Receives FDA Clearance
February 16, 2023—Perfuze, an Ireland-based medical device company, announced that its Millipede 088 access catheter was granted United States FDA 510(k) clearance for use in treating acute ischemic stroke.
Rapid Medical’s Tigertriever 13 Evaluated in Interim Safety Analysis From DISTALS Study
September 4, 2024—Rapid Medical announced completion of the interim safety analysis of the DISTALS study at the European Society of Minimally Invasive Neurological Therapy’s ESMINT Congress 2024 held September 4-6 in Marseilles, France.
Balt’s Squid Liquid Embolic for Treating cSDH Evaluated in Published STEM Trial
December 3, 2024—Balt, Inc., developer of the investigational Squid liquid embolic, recently announced the publication of STEM—the Squid trial for the embolization of the middle meningeal artery (MMA) for the treatment of chronic subdural hematoma (cSDH).
Mentice to Acquire Vascular Simulations
October 1, 2020—Mentice AB announced it has entered into a definitive agreement to acquire Vascular Simulations, Inc. (VSI).
IDE Granted for New 0.021-Inch Devices in Sequent Medical's WEB-IT Study
October 12, 2015—Sequent Medical announced that the US Food and Drug Administration has approved the inclusion of the company’s Web 0.021-inch devices for use in the WEB-IT (Web intrasaccular therapy) United States investigational device exemption (IDE) clinical study, which began enrollment in August 2014.
Perfuze’s Millipede Aspiration and Access Catheters Cleared by FDA for Neurovascular Interventions
December 20, 2023—Perfuze announced that the second generation of its Millipede 088 access catheter and its Millipede 070 aspiration catheter have received FDA 510(k) clearance.
DISTALS Trial of Rapid Medical’s Tigertriever 13 Completes Enrollment
December 9, 2025—Rapid Medical announced the completion of patient enrollment in the multicenter, randomized DISTALS trial assessing the company’s Tigertriever 13 device to treat patients with distal medium vessel occlusions (DMVO) in acute ischemic stroke.
RapidAI’s Rapid ICH Product Cleared by FDA for Intracranial Hemorrhage Management
November 9, 2022—RapidAI announced it has received FDA 510(k) clearance for the latest release of Rapid ICH, the company’s intracranial hemorrhage (ICH) triage and notification product.
